Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: pimavanserin tartrate Clear all
Completed Phase 4 Interventional Results available

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

NCT04292223
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Scottsdale, Arizona • Fullerton, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

NCT03575052
View directory record Official record
Conditions
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
60 Years and older
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Costa Mesa, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 4 Interventional Results available

Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder

NCT04188392
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Insomnia
Interventions
Pimavanserin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 7, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional

Pimavanserin for Insomnia in Veterans With PTSD

NCT05441280
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Insomnia
Interventions
pimavanserin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 7, 2026, 3:33 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Psilocybin Efficacy With or Without Pimavanserin Pretreatment

NCT07610135
View directory record Official record
Conditions
Mood (Psychological Function), Well Being, Mood, Healthy
Interventions
Psilocybin, Pimavanserin, Inactive Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 7, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pimavanserin and Aggression and Social Cognition.

NCT05895513
View directory record Official record
Conditions
Intermittent Explosive Disorder
Interventions
Pimavanserin 34 mg, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

NCT00550238
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
83
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 7, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional

Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

NCT06592833
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin, Pimavanserin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

NCT00361166
View directory record Official record
Conditions
Schizophrenia
Interventions
ACP-103
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Cerritos, California • Garden Grove, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2007 · Synced Oct 7, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

NCT04164758
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Pimavanserin, Placebo, Quetiapine
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

ACP-103 to Treat Parkinson's Disease

NCT00086294
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesias
Interventions
Intravenous Levodopa, ACP-103
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

NCT03623321
View directory record Official record
Conditions
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
60 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Gilbert, Arizona • Costa Mesa, California • Santa Ana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

NCT01518309
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

NCT03118947
View directory record Official record
Conditions
Agitation and Aggression in Alzheimer's Disease
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Costa Mesa, California • Fresno, California • Fullerton, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 7, 2026, 3:33 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT04000009
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Garden Grove, California • Glendale, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 7, 2026, 3:33 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

NCT05555615
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 18 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • San Rafael, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 7, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

NCT05999240
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID], Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Lawrence, Kansas • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 7, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional Results available

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

NCT02992132
View directory record Official record
Conditions
Agitation and Aggression in Alzheimer's Disease
Interventions
Pimavanserin 34 mg, Pimavanserin 20 mg, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
33
States / cities
Costa Mesa, California • Fresno, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 7, 2026, 3:33 AM EDT
Recruiting Phase 4 Interventional

Comparing Antipsychotic Medications in LBD Over Time

NCT05590637
View directory record Official record
Conditions
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Early Phase 1 Interventional

Pimavanserin Treatment in TS

NCT04794413
View directory record Official record
Conditions
Tourette Syndrome, Tardive Dyskinesia
Interventions
Pimavanserin
Drug
Lead sponsor
Joseph Jankovic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

NCT05523895
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • San Rafael, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

NCT00087542
View directory record Official record
Conditions
Hallucinations, Psychoses, Parkinson's Disease
Interventions
ACP-103
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
Fountain Valley, California • Sunnyvale, California • Danbury, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2005 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

NCT01174004
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
pimavanserin tartrate, placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
62
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 7, 2026, 3:33 AM EDT